Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Nanoliposomal Irinotecan (Nal-IRI ONIVYDE ) in Combination With TAS-102 (LONSURF ) in Refractory Solid Tumors

The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an effective regimen that could be applied to various cancers

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and TAS 102) no longer have treatment options available while maintaining

  • 25 views
  • 28 Apr, 2021
  • 1 location
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

study will also compare lenvatinib plus pembrolizumab with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil hydrochloride). The primary study hypothesis is

  • 0 views
  • 14 May, 2021
  • 30 locations
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687 subjects will be randomized to one of the following treatment arms in …

biological therapy
adjuvant therapy
fluoropyrimidine
adenocarcinoma
metastatic colorectal adenocarcinoma
  • 0 views
  • 30 Apr, 2021
  • 139 locations
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer. TAS

  • 6 views
  • 23 Jan, 2021
  • 1 location
TAS 102 in Combination With Ramucirumab in Advanced Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ

cancer chemotherapy
neutrophil count
renal function
cancer
solid tumour
  • 10 views
  • 12 Feb, 2021
  • 1 location
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

This phase 1b trial studies the side effects and best dose of TAS-102 when given together with radiation therapy in treating patients with stage II-III rectal cancer that has not been treated

metastasis
tumor cells
neutrophil count
rectal carcinoma
rectal tumor
  • 0 views
  • 26 Jan, 2021
  • 1 location
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different

tumor cells
neutrophil count
irinotecan
ras mutation
trifluridine and tipiracil hydrochloride
  • 0 views
  • 01 Mar, 2021
  • 2 locations
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

with locally advanced or metastatic adenocarcinoma, plus TAS-102 shows good tolerability without safety issues regarding the serious adverse event rate of any cause, and whether the combination shows

metastasis
aptt
international normalized ratio
liver metastasis
neutrophil count
  • 0 views
  • 26 Jan, 2021
  • 5 locations
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

, oxaliplatin, anti-VEGF therapy and anti-EGFR therapy (for tumours with wild-type KRAS)); randomized for treatment with TAS-102 (standard-arm) or High Dose Intermittent Sunitinib (700 mg once every 2 weeks

  • 0 views
  • 26 Jan, 2021
  • 1 location